e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:ETX
- CUSIP: N/A
- Web: N/A
- Market Cap: £20.47 million
- Outstanding Shares: 268,426,000
- 50 Day Moving Avg: GBX 8.24
- 200 Day Moving Avg: GBX 8.31
- 52 Week Range: GBX 7 - GBX 14.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.06 per share
- Price / Book: 1.27
- Average Volume: 35,597 shs.
Frequently Asked Questions for e-Therapeutics plc (LON:ETX)
What is e-Therapeutics plc's stock symbol?
e-Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "ETX."
Who are some of e-Therapeutics plc's key competitors?
Some companies that are related to e-Therapeutics plc include Cerillion PLC (CER), Beowulf Mining plc (BEM), Trans-Siberian Gold plc (TSG), Shanta Gold Limited (SHG), Plant Health Care plc (PHC), Mytrah Energy Ltd (MYT), AFC Energy plc (AFC), Volex PLC (VLX), Chariot Oil & Gas Limited (CHAR), Private & Commercial Finance Group plc (PCF), ANGLE plc (AGL), Good Energy Group Plc (GOOD), Bioquell plc (BQE), Escher Group Holdings plc (ESCH), The Mission Marketing Group plc (TMMG), Trakm8 Holdings PLC (TRAK), French Connection Group (FCCN) and eServGlobal Limited (ESG).
How do I buy e-Therapeutics plc stock?
Shares of e-Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of e-Therapeutics plc stock cost?
One share of e-Therapeutics plc stock can currently be purchased for approximately GBX 7.63.
Consensus Ratings for e-Therapeutics plc (LON:ETX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for e-Therapeutics plc (LON:ETX)
(Data available from 5/27/2015 forward)
|8/17/2015||N+1 Singer||Reiterated Rating||Corporate|
Earnings History for e-Therapeutics plc (LON:ETX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for e-Therapeutics plc (LON:ETX)
Current Year EPS Consensus Estimate: $-3.600 EPS
Dividend History for e-Therapeutics plc (LON:ETX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for e-Therapeutics plc (LON:ETX)Insider Trades by Quarter for e-Therapeutics plc (LON:ETX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/12/2017||Trevor Mervyn Jones||Insider||Buy||59,400||GBX 8||£4,752|
|1/3/2017||Trevor Mervyn Jones||Insider||Buy||36,917||GBX 7||£2,584.19|
|1/21/2015||Steve Medlicott||Insider||Buy||150,000||GBX 25.25||£37,875|
Headline Trends for e-Therapeutics plc (LON:ETX)
Latest Headlines for e-Therapeutics plc (LON:ETX)
e-Therapeutics plc (ETX) Chart for Saturday, May, 27, 2017